Fig. 6: Trifluoperazine (TFP) corrects the aberrantly elevated Akt and S6K1 activity in Fmr1 KO mice.

Wild type (WT) and Fmr1 KO (Fmr1) mice were injected with vehicle or trifluoperazine (0.05 mg/kg) 1 h before hippocampus was harvested. The levels of total Akt (a, b) and phosphorylated Akt (pAkt) (a, c) as well as total S6K1 (d, e) and phosphorylated S6K1 (pS6K1 at Thr389) (d, f) were determined by Western blot. Protein loading was determined by the level of β-actin (a, d). The expression of FMRP was detected in WT but not Fmr1 KO samples by Western blot (a, d). The genomic differences in WT and Fmr1 KO samples were further confirmed by PCR-base genotyping; the PCR product is 130 bp for WT and 420 bp for Fmr1 KO samples (the bottom panel a, d). Representative images are shown in a, d. For quantification, the level of total Akt (b) and total S6K1 (e) was normalized to the level of β-actin. The level of pAkt (c) and pS6K1 (f) was normalized to the level of total Akt and total S6K1, respectively. The relative level of Akt (or pAkt) and S6K1 (or pS6K1) in the vehicle-treated wild type (WT) group was defined as 1, and all samples were normalized to this group. The p values were determined by two-way ANOVA (b, e) or two-way ANOVA followed by Holm-Sidak test (c, f).